Drug intelligence / Profile preview

SBP-303

Development stage: Preclinical
Lead developer: SML Biopharm
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SBP-303 is an mRNA-based bispecific antibody (bsAb) candidate developed by SML Biopharm for the treatment of solid cancers. It is part of the company's 'In-vivo Protein Expression Therapeutics' pipeline, which utilizes a proprietary mRNA/LNP (lipid nanoparticle) platform. The therapeutic approach involves delivering mRNA encapsulated in LNPs to direct host cells to express and secrete a bispecific antibody in vivo, potentially offering advantages in manufacturing and pharmacokinetics over traditional recombinant protein therapies. As of the latest reports, SBP-303 is in the candidate optimization stage of development.

Beyond the preview

Go deeper on SBP-303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-303.

Explore the full profile